Combination of Imaging, Biomarkers Offers Better Assessment of ALS Patients, Study Finds

Combining structural brain imaging with molecular and clinical biomarkers allows for a detailed assessment of a patient’s clinical state, regardless of age and amyotrophic lateral sclerosis progression, a new study suggests. The study, “Combinatory Biomarker Use of Cortical Thickness, MUNIX, and ALSFRS-R at Baseline and in Longitudinal Courses of…

“Humility is nothing but truth, and pride is nothing but lying.” ―St. Vincent de Paul I never knew the comical extent of my pride until ALS hit me. Prior to its impact on my life, I prided myself on my independence and the manner by which I presented myself to the…

Treatment with extracts from the Withania somnifera plant improved motor performance and delayed disease progression in mice with amyotrophic lateral sclerosis (ALS), according to researchers. The study, “Protective effects of Withania somnifera extract in SOD1G93A mouse model of amyotrophic lateral sclerosis,” was published in the journal Experimental Neurology. ALS generally develops sporadically, indicating that in…

A newly developed test, known as the arrows and colors cognitive test, can be used to measure cognition in amyotrophic lateral sclerosis (ALS) patients who have severe motor and verbal disabilities. A study about that assessment tool, “The Arrows and Colors Cognitive Test (ACCT): A new verbal-motor free cognitive…